← All stories
Markets 1 sources

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?

Covered by 1 source · 1 article

Covered by

All coverage

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?
Yahoo Finance News Aug 22, 00:53 UTC

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?